Why Your DNA is a Goldmine for Marketers
By Carolyn Abraham,
The Globe and Mail
| 12. 12. 2012
[Quotes CGS's Marcy Darnovsky]
David Pike prefers hiking holidays over seaside lounging, and personalized ads over random promotions. “Show me the trails of Madeira,” says the St. John’s mathematics professor, describing the sort of marketing campaign he finds most appealing, “not the sandy beaches of Jamaica.”
One day in the not-too-distant future, marketers might turn to an unexpected source for clues to Prof. Pike’s vacation preferences: his chromosomes.
In the ever-growing field of personal-data mining, marketing firms already latch on to details far beyond the sphere of names and postal codes to gain insights into consumers’ personal tastes. And DNA may well be the next frontier: genetic information gleaned from burgeoning databases. Prof. Pike and thousands of others, for instance, have contributed their DNA for ancestry or health tests. And Canadian volunteers are now signing up for the newly launched Personal Genome Project, which is to house an online open storehouse of genetic codes and personal traits.
If that sounds far-fetched, consider this: Two years ago, just a decade after the first human genome was mapped, Visa Inc., one of the world’s largest credit-card...
Related Articles
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...